Treatment of portal hypertension in the light of the Baveno VI Consensus Conference by Tcaciuc, Eugen
REvIEw ARTIClES Curierul medical, December 2015, Vol. 58, No 6
Treatment of portal hypertension 
in the light of the Baveno VI Consensus Conference
E. Tcaciuc
Department of Internal Medicine, Medical Clinic No 3
Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova
Corresponding author: eugentcaciuc@yahoo.com. Received October 15, 2015; accepted November 27, 2015
Abstract
Background: Portal hypertension is the haemodynamic abnormality associated with the most severe complications of cirrhosis, including ascites, hepatic 
encephalopathy and bleeding from gastro-oesophageal varices. Pharmacological and endoscopic treatment of portal hypertension has played an increasing 
clinical role in the past 30 years. Despite the progress achieved over the last decades, the 6-week mortality associated with variceal bleeding is still in 
the order of 10–20%. In the setting of acute variceal bleeding, drug and endoscopic therapy should be considered the initial treatment of choice and can 
be administered as soon as possible. Management of treatment of portal hypertension and variceal hemorrhage is based on the clinical stage of portal 
hypertension. Prevention of first variceal hemorrhage depends on the size of varices. In pa tients with small varices and high risk of bleeding, non-selective 
β-blockers are recommended, while patients with medium/large varices can be treated with either β-blockers or oesophageal band ligation. Standard of 
care for acute variceal hemorrhage consists of vasoac tive drugs, endoscopic band ligation and antibiotics prophylaxis. Patients who had failed this therapy 
should be considered for transjugular intrahepatic portosystemic shunt or shunt surgery. Prevention of recurrent variceal hemorrhage consists of the 
combination of β-blockers ± isosorbide 5-mononitrate and endoscopic band ligation. Patients with recurrent variceal hemorrhage are in a category of 
“further decom pensation” of cirrhosis and, as such, should be evaluated for liver transplantation.
Conclusions: In the last decades significant advances in the field of portal hypertension have improved the clinical care and survival of patients with 
cirrhosis and portal hyper tension. Further research is necessary to explore new pharmacologi cal options that would allow to get a positive hemodynamic 
response in most patients.
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History consensus conferences dedicated 
to the treatment of portal hypertension
The management of portal hypertension is linked with so-
called “Baveno consensus” that serves as an important basis 
for developing guidelines and clinical protocols in this area. 
Baveno is a small town in northern Italy situated on the west 
Shore of Maggiore Lake. It became the epicenter of consensus 
workshops dedicated to portal hypertension, which aim is to 
reach a common denominator about definitions and the most 
important events associated with portal hypertension and 
variceal bleeding. The first workshop dedicated to Baveno 
consensus was held in April 1990 [1], in which were evaluated 
significant progress in terms of diagnosis and management 
of eso-gastric varices and variceal bleeding, including the 
administration of vasoactive drugs and the use of endoscopic 
sclerotherapy. Additionally, were defined certain features and 
complications of portal hypertension including the varices 
sizes, the bleeding and its recurrences, the recommendations 
about diagnosis methods and were traced new directions 
for future clinical studies. Therapeutic recommendations 
included the following: β-blockers for primary prophylaxis 
of bleeding from large varices, endoscopic sclerotherapy and 
vasoactive drugs for acute variceal bleeding, and to prevent 
recurrent bleeding – endoscopic sclerotherapy, β-blockers or 
surgical shunt.
The Baveno II workshop was held in April 1995 [2]. Were 
revised definitions of the most important clinical syndromes 
in portal hypertension and new definitions were proposed. 
After analyzing several randomized controlled trials, nonse-
lective β-blockers were recommended as the elective treatment 
for primary prevention of variceal bleeding, while isosorbide-5 
mononitrate has been recommended in patients who were 
intolerant or had contraindications to β-blockers. Endosco-
pic sclerotherapy was not recommended for the prevention 
of the first episode of bleeding. While the treatment of acute 
bleeding was based on endoscopic therapy, on terlipressin 
administration (which was considered one of the most effec-
tive vasoactive agents) and somatostatin analogues. TIPS has 
been recommended in case of failure of endoscopic and phar-
macological treatment. The recommendations related to the 
prevention of recurrent bleeding include the administration 
of β-blockers or endoscopic variceal ligation, which it has 
shown to be more effective and safer than sclerotherapy [3]. 
TIPS and surgical shunt followed to be used only for patients 
with frequent repeated episodes of variceal bleeding.
The Baveno III Conference was held in April 2000 
[4], where it was introduced the concept of portal hyper-
tension with significant clinical manifestations, which is 
determined if hepatic venous pressure gradient (HVPG) 
≥ 10 mmHg. The presence of varices, variceal bleeding or 
ascites indicates the portal hypertension with significant 
clinical manifestations. Nonselective β-blockers were kept 
in elective treatment for preventing the first episode of 
bleeding from large/medium varices, while the endoscopic 
variceal ligation was considered necessary for an additional 
evaluation. Were defined the targets of β-blockers therapy 
(25% reduction in heart rate from baseline or establishing 
a heart rate of 55 beats/min). It was not proposed the using 
of isosorbide-5 mononitrate as an alternative treatment, 
which was previously recommended [5]. For the acute ble-
eding treatment, immediate administration of vasoactive 
medications and the continuation over 5 days together with 
endoscopic therapy (endoscopic variceal ligation or sclero-
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therapy) were considered as the standard. Also, were pro-
posed some additional measures: antibiotic use to prevent 
bacterial infection [6] and the lactulose for the treatment of 
hepatic encephalopathy. About the prevention of repeated 
bleeding, β-blockers were considered first-line therapy [7], 
in parallel with endoscopic variceal ligation, and TIPS was 
reserved in the case of treatment failure. Also, were clearly 
defined the complications of portal hypertension and were 
proposed targets for further research.
The Baveno IV Conference was held in April 2005 [8], 
there were revised some key criteria (inability to control 
bleeding, the failure of secondary prevention). For primary 
prevention, β-blockers were kept as an elective treatment, but 
endoscopic ligation was placed as an excellent alternative for 
patients with large and medium varices and contraindications 
or intolerance to β-blockers [9, 10]. Isosorbide 5-mononitrate, 
was not recommended either in monotherapy, or even in 
a combination of pharmacological therapies [11]. Primary 
prevention of small varices can be considered only if they are 
at high risk for hemorrhage (“red signs” or Child-Pugh Class 
C) [12]. The recommendations for acute variceal bleeding 
were kept the same as in the Baveno III Consensus. Along 
with vasoactive drugs administration for at least 5 days, it was 
recommended the use of tamponade with balloon and only in 
massive bleeding as a temporary bridge until the establishment 
of defenitive treatment. The endoscopic variceal ligation was 
declared superior to sclerotherapy and was considered the 
elective endoscopic procedure for acute bleeding control [10, 
13]. It is recommended that secondary prophylaxis should be 
initiated by the 6th day after variceal hemorrhage, which must 
include a combination of endoscopic ligation and nonselective 
β-blockers [14, 15]. As in previous consensuses, TIPS and 
surgical shunts were reserved for patients with secondary 
prevention failure.
The Baveno V Conference of May 2010 revised the defi-
nitions relating to the failure of variceal bleeding control and 
secondary prophylaxis [16]. Primary prophylaxis recommen-
dations for small varices were the same as in the previous 
consensuses. There was no significant change in the recom-
mendations for primary prevention of medium and large va-
rices (β-blockers or endoscopic variceal ligation). The choice 
of therapy was dictated by local resources, the experience of 
specialists and patient preference [17]. The recommendations 
for treatment of acute variceal bleeding were unchanged, 
except a recommendation, which involves the use of TIPS in 
the early period (in 72 hours) in patients with increased risk 
of pharmacological or endoscopic treatment failure [18]. For 
preventing recurrent bleeding was proposed the combination 
therapy of β-blockers and endoscopic variceal ligation.
The Baveno VI Consensus Conference took place in April 
2015. Below are outlined the basic principles of modern ma-
nagement of portal hypertension.
Standard modern treatment  
of portal hypertension in adults
The therapy of esophageal varices and variceal bleeding in 
adult patients with cirrhosis should be differentiated according 
to clinical stages of the natural history of portal hypertension 
which were divided into 4 stages:
1. Patients with cirrhosis and portal hypertension, which 
has not yet developed varices and the therapy purpose is to 
prevent the formation of varices (pre-primary prophylaxis).
2. Patients with esogastric varices which are not bleeding 
and the therapy purpose is to prevent their rupture (primary 
prevention).
3. Patients with acute variceal hemorrhage for which the 
objective of treatment is to stop the bleeding and prevent its 
recurrence in the early period.
4. Patients who had survived an acute variceal bleeding 
and the goal of therapy is to prevent recurrence of bleeding 
in the late period (secondary prevention).
The prevention of the esogastric varices formation 
(pre-primary prophylaxis)
Each new patient diagnosed with cirrhosis requires the 
effectuation of upper gastrointestinal endoscopy for the 
identification of varices presence and their degree. Large, 
multicenter, randomized and controlled trials found no 
difference between placebo and β-blockers in preventing 
the formation of varices in patients who have not developed 
esogastric varices [19]. Therefore, no specific treatment for 
portal hypertension is recommended in these patients. The 
main focus at this stage is to treat the underlying cause of 
cirrhosis, which will reduce portal hypertension and therefore 
will prevent the development of clinical complications.
The prevention of the first variceal bleeding  
(primary prevention)
The first variceal hemorrhage occurs with an annual 
rate about 15%, although currently mortality after a variceal 
bleeding is lower than in the last two decades, however, re-
mains significant (7% – 15%) [20 – 22] and it is associated 
with significant morbidity and high costs for treatment. The 
prevention of the first episode of bleeding, therefore, is an 
important part of the portal hypertension treatment. The 
size of varices, “red signs” on varices (endoscopic view) and 
severity of liver disease (Child-Pugh C class) identifies patients 
with the highest risk of variceal hemorrhage [12]. Therefore, 
at this stage, patients must be differentiated depending on 
the risk of bleeding:
• high-risk patients (those with medium/large varices or tho-
se with small varices, but with “red signs” or evolutionary 
stage Child-Pugh C ).
• low-risk patients (those with small varices without “red 
signs” or which appear in patient with Child-Pugh A or 
B class).
Several studies had demonstrated that for patients with 
medium/large varices, the nonselective β-blockers (propra-
nolol, nadolol) are as effective as endoscopic variceal ligation 
in the prevention of first variceal bleeding [23, 24], but the 
author’s recommendations are based on using the therapy 
according to existing local resources, the specialist experience 
in this area and patient preference.
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For patients with increased risk of bleeding and a low de-
gree of varices the principal therapeutic options is nonselective 
β-blockers administration, and the application of endoscopic 
variceal ligation is difficult.
For patients with low risk of hemorrhage and small varices 
there is limited evidence demonstrating that their growth can 
be slowed by using nonselective β-blockers [25]. Therefore, 
the use of nonselective β-blockers in this case is considered 
optional and should be discussed with the patient.
For primary prevention the starting dose of propranolol 
administration is 20 mg orally 2 times a day. Dosage adjust-
ment is made every 2–3 days until the target dose is reached, 
which decreases the heart beats by 25% from the initial, but 
must not fall below 50 – 55 beats/minutes. The maximum 
dose does not exceed 320 mg. At each ambulatory visit it 
is necessary to adjust the dose of β-blocker. In the absence 
of contraindications the treatment is indefinite. Nadolol is 
administered in a 40 mg dose in a single dose and the ma-
ximum dose should not exceed 160 mg. Dose adjustments 
are performed as in the case of propranolol administration. 
Endoscopic variceal ligation is performed every 2 – 4 weeks 
until the final variceal obliteration. The repeating of endo-
scopy is made over 1 – 3 months after obliteration and later 
over every 6 – 12 months.
For secondary prophylaxis, the management of nonselec-
tive β-blockers administration and endoscopic procedures is 
the same as in primary prevention. Isosorbide-5-mononitrate 
may be associated with non-selective β-blockers initially in 
a dose of 10 mg orally at night, and then 10 mg orally twice 
a day with a maximum dose of 20 mg twice a day. Systolic 
blood pressure should not fall below 95 mmHg. The duration 
of therapy with isosorbide-5-mononitrate is also indefinite.
Nonselective β-blockers decrease portal pressure by redu-
cing portal blood flow. Their mechanism of action involves 
the decreasing of cardiac output by blocking β1 receptors, but 
splanchnic vasoconstriction is achieved by blocking β2 recep-
tors. The latter is the most important effect of nonselective 
β-blockers in portal hypotensive therapy (unlike the selective 
β-blockers). Nonselective β-blockers advantages include low 
cost and simplicity of administration. Because nonselective 
β-blockers decrease the degree of portal hypertension, their 
use may also reduce other complications of cirrhosis, such 
as bleeding from eso-gastric varices and portal-hypertensive 
gastropathy, ascites and spontaneous bacterial peritonitis [26, 
27]. It was found that, in fact, a significant reduction in portal 
pressure was associated with the improvement of survival in 
patients with liver cirrhosis [28]. In addition, in the opinion 
of some authors, once the patient administers nonselective 
β-blockers it is not necessary to repeat endoscopy.
Endoscopic variceal ligation has some advantages: during 
the procedure can be examined the whole upper digestive tract 
mucosa, has relatively few contraindications and a lower inci-
dence of side effects compared to nonselective β-blockers [9].
The main disadvantage of nonselective β-blockers is that 
approximately 15% of patients may have absolute or relative 
contraindications to the therapy administration and the other 
15% require dose reduction or discontinuation of therapy due 
to frequent side effects (eg, fatigue, weakness, bronchospasm) 
that disappear after stopping these medicines [17].
Endoscopic variceal ligation risks include those related 
to endoscopic procedures and sedation (bleeding, aspirati-
on, perforation and reaction to medications), along with the 
risk of bleeding from ulcers induced by the ligation. In fact, 
although the number of side effects is higher in nonselective 
β-blockers administration than after endoscopic variceal 
ligation [9], the severity of side effects is higher in perfor-
ming the latter. Fatal side effects after using the non-selective 
β-blockers have been not reported, but have been reported 
deaths resulting from endoscopy procedures (e.g., bleeding 
from ulcers induced by varices ligation) [9, 10].
It is certain that the ideal portal hypotensive therapy has 
not been established. There are medical centers where is 
preferred endoscopic variceal ligation, while in other centers 
prefer to start with nonselective β-blockers, and then, if ne-
cessary, the use of endoscopic variceal ligation.
Carvedilol is a nonselective β-blocker, possessing additi-
onal vasodilating effect through anti-α1-adrenergic activity. 
There is evidence that carvedilol administration in portal hy-
potensive purpose is more effective than endoscopic variceal 
ligation in preventing first variceal bleeding [29]. Although 
the use of carvedilol is considered a promising alternative, 
it is necessary to perform further research before it can be 
widely recommended.
The management  
of acute variceal hemorrhage
Acute variceal hemorrhage is a major medical emergency 
requiring intensive care. First, the basic treatment is directed 
to achieve hemodynamic stability. Blood transfusion is done to 
raise hemoglobin levels between 70 – 80 g/l [30], because the 
return of excessive blood volume can increase portal pressure 
[31, 32]. The survival is higher in patients with variceal hemor-
rhage submitted to restrictive transfusion policy. Restrictive 
transfusions significantly reduce mortality, particularly in 
Child-Pugh A and B cirrohosis [33].
It is necessary to correct coagulation disorders, although, 
currently, there are no clear recommendations on the ma-
nagement of coagulopathy and thrombocytopenia [34, 35].
Antibiotic prophylaxis is an integral part of therapy for 
patients with liver cirrhosis and upper gastrointestinal blee-
ding since the admission. Antibiotic prophylaxis is provided 
by quinolones and/or ceftriaxone in i/v administration [6, 36]. 
The risk of bacterial infections and mortality is reduced in 
patients Child-Pugh A, but are necessary prospective studies 
that can demonstrate that antibiotico-prophylaxis may be 
excluded from this group of patients.
Vasoactive medication needs to be started as soon as 
possible, even before diagnostic endoscopy. Endoscopy also 
is made as soon as possible and not later than 12 hours after 
addressing. If the bleeding source is identified, the elective 
procedure is endoscopic variceal ligation, but sclerotherapy 
is an option when ligation is technically difficult. TIPS is 
recommended in patients failing standard therapy (a com-
bination of endoscopic and pharmacological treatment). 
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However, TIPS has a high mortality. The predictive factors 
of standard therapy failure are Child-Pugh C class, HVPG > 
20 mmHg, and active bleeding on endoscopy [37]. Using the 
TIPS in the early period (approximately 48 hours of onset) 
in patients with increased risk of failure to standard therapy, 
significantly reduces mortality [18]. It occurs in patients with 
evolutionary stage Child-Pugh C (score 10 – 13 points) or 
evolutionary stage Child-Pugh B with active bleeding (at the 
moment of diagnostic endoscopy) and represents <20% of 
patients with variceal bleeding. In these patients it is recom-
mended to consider the possibility of TIPS effectuation. The 
rest of the patients need to continue the standard therapy with 
vasoactive drugs for 2 – 5 days continually, depending on the 
bleeding control and the severity of liver disease. Vasoactive 
drugs may be discontinued once the patient had no bleeding 
for at least 24 hours. The tamponade with balloon is used only 
as a temporary measure (balloons are inflated for 12 hours 
or less) to control bleeding, while is planned the definitive 
treatment (TIPS or endoscopic therapy). A new esophageal 
stent was proposed last year that can replace the tamponade 
with ballon [38].
Although there are pros and cons for each of these first-line 
therapies, current recommendations are for the combination 
of pharmacological and endoscopic methods to effectively 
control acute hemorrhage.
Vasoactive agents improve the control of variceal blee-
ding when are combined with endoscopic therapy in com-
parison with application of endoscopic therapy exclusively 
[39]. However, there is a significant difference between 
various vasoactive agents on controlling bleeding and early 
rebleeding. Vasopressin is a powerful vasoconstrictor, but 
because it is associated with more side effects [40] it is not 
considered as vasoactive drug for first-line. Its use is limited 
because of many side effects associated with splanchnic 
vasoconstriction (for example, intestinal ischemia) and 
systemic vasoconstriction (e.g., hypertension, myocardial 
ischemia). However, in case of using vasopressin, it must 
be taken with nitroglycerin.Terlipressin is an analogue of 
vassopresin and represents a pharmacological agent which 
demonstrated in comparative studies the improvement 
of survival in patients with variceal hemorrhage [40]. 
It possess splanchnic vasoconstrictor effect. The active 
metabolite of terlipressin, lysine-vasopressin, is released 
gradually over several hours thus reducing typical side 
effects of vasopressin. Terlipressin is administered 2 mg i/v 
in bolus, and 2 mg every 4 hours during a bleeding episode. 
For the prevention of rebleeding the maintenance doses are 
1 mg/4 hours i/v bolus up to 5 days.
Somatostatin inhibits the vasodilatory substances, such 
as glucagon, causing splanchnic vasoconstriction and the 
decrease of portal blood flow. Initially, is administered 250 
pg i/v in bolus followed by continuous infusion from 250 pg 
to 500 pg/hour up to 5 days.
Octreotide is a somatostatin analogue and has the same 
mechanism of action as somatostatin, but a longer duration of 
action. Initially, is administered 50 μg i/v in bolus, then each 
50 μg/hour in continuous infusion up to 5 days.
Vapreotide is also an analogue of somatostatin with the 
same mechanism of action but with a higher metabolic 
stability. Initially it is administered 50 μg i/v in bolus, then 
each 50 μg/hour in continuous infusion up to 5 days. The 
main side effects of somatostatin analogues (octreotide and 
vapreotide) are sinus bradycardia, hypertension, arrhythmias 
and abdominal pain.
In practice, the choice of a pharmacological agent is based 
usually on availability and cost.
So, the preferable treatment of acute variceal hemorrhage 
is combined: vasoactive drugs administered before the effec-
tuation of endoscopy and emergency endoscopic therapy. 
Pharmacological elective therapy is represented by terlipressin 
(lower mortality in placebo-controlled trials) or somatostatin 
and octreotide (fewer side effects). The elective endoscopic 
therapy is endoscopic variceal ligation.
Recommendations can vary according to the severity 
of liver disease. In patients who are in evolutionary stage of 
cirrhosis Child-Pugh C (or Child-Pugh B with active blee-
ding), the risk of standard therapy failure (vasoactive drugs 
plus endoscopic variceal ligation) is large and therefore it is 
appropriate to pass to “rescue” therapy (i.e., TIPS) before we 
get a failure of standard therapy. Patients in Child-Pugh A 
class, the mortality after standard treatment is around zero [20, 
22], and these patients may respond to vasoactive treatment 
in monotherapy, although this requires further researches.
The prevention of variceal hemorrhage recurrence 
(secondary prevention)
The risk of rebleeding in patients who have suffered a 
variceal bleeding is high (average rate of rebleeding is 60%), 
with a mortality of up to 33%. The prevention of rebleeding 
is therefore an essential part of the management in patients 
with variceal bleeding. Patients in the acute episode of ble-
eding who benefited from TIPS, do not require a specific 
hypotensive therapy or endoscopic surgery on varices, but 
should be cautious for transplant. TIPS’s permeability should 
be checked by Doppler ultrasonography every 6 months. For 
most patients (who have not been effectuated TIPS during an 
acute episode of bleeding), the secondary prophylaxis with 
nonselective β-blockers should be started as soon as possible, 
but after intravenous vasoactive drug administration is discon-
tinued. Nonselective β-blockers significantly reduce the risk of 
recurrent bleeding [7]. Although, according to several studies, 
the addition of isosorbide 5-mononitrate with nonselective 
β-blockers has a greater effect on reducing portal pressure 
[41], in clinical trials the combination of these groups is not 
different from monotherapy with nonselective β-blockers 
in terms of rate rebleeding or death, but has a higher rate of 
side effects [42].
The sclerotherapy decreases the rate of bleeding and the 
mortality, but is associated with serious complications (eg., 
esophageal stricture, bleeding from ulcer). Sclerotherapy has 
been replaced with endoscopic variceal ligation because the 
ligature showed significantly better results in comparison with 
sclerotherapy about rebleeding, mortality and side effects. 
Several studies have compared pharmacological treatment 
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(nonselective β-blockers in addition with isosorbide 5-mo-
nonitrate) versus variceal endoscopic ligation and found 
that there are no significant differences in the occurrence 
of recurrent haemorrhage, but long-term administration of 
pharmacological treatment has a beneficial effect on patient 
survival [43]. It was found that the combination of pharma-
cological treatment (nonselective β-blockers in monotherapy 
or nonselective β-blockers + isosorbide 5-mononitrate) plus 
endoscopic variceal ligation is associated with lower rates of 
rebleeding than pharmacological or endoscopic monotherapy 
[44, 45] and it is an elective option.
If patients have and recurrent variceal hemorrhage despite 
of combined pharmacological and endoscopic treatment, is 
indicated the application of TIPS with polytetrafluoroethy-
lene-covered stents [46] or, if necessary, surgical shunts [47].
Pharmacologic agents give protection against rebleeding 
both in the period up to the first variceal bleeding and in the 
period of recurrence prevention, with or without the effectu-
ation of endoscopic variceal ligation. It is considered useful to 
give nonselective β-blockers in monotherapy or in combina-
tion with isosorbide 5-mononitrate. The choice of treatment 
tactics depends on patient tolerability. Patients who are not 
candidates for endoscopic variceal ligation should adminis-
trate the combined drug therapy (nonselective β-blockers + 
isosorbide 5-mononitrate).
The lowest rates of variceal bleeding recurrences (about 
10%) are observed in people who have a positive hemody-
namic response to pharmacological treatment, defined as a 
decrease in HVPG under 12 mmHg or a decrease of more 
than 20% from baseline of HVPG [28, 48]. It is reasonable 
to guide pharmacological therapy according to hemodyna-
mic response and, therefore, patients who achieve a positive 
hemodynamic response do not require endoscopic therapy. 
Patients who are intolerant or have contraindications to 
pharmacological therapy should receive endoscopic vari-
ceal ligation in monotherapy.
Some researchers have observed that the administration 
of non-selective β-blockers in patients with refractory asci-
tes is associated with a lower survival than patients without 
refractory ascites [49]. However, it is noted that patients with 
refractory ascites have a higher prevalence of varices and, 
particularly, those with an increased risk of bleeding, which 
leads to a higher mortality. So now, even these patients may 
benefit from treatment with nonselective β-blockers [7, 50] 
and therefore nonselective β-blockers are not contraindicated 
in patients with refractory ascites. It is necessary to note that 
combined treatment with nonselective β-blockers and isosor-
bide 5-mononitrate has a higher incidence of superimposed 
side effects caused by isosorbide 5-mononitrate association, 
usually manifested by headaches and dizziness. As mentio-
ned above, the lowest rate of rebleeding is in patients with a 
positive hemodynamic response. On the other hand, while 
HVPG guiding therapy seems to be rational, a small study 
showed that HVPG guiding therapy results are not different 
from combined endoscopic and pharmacological treatment 
[51]. Although HVPG determination is standardized and it 
is performed widely in large clinical centers, HVPG guiding 
therapy has not yet been introduced in the guidelines recom-
mendations[52].
As mentioned above, endoscopic variceal ligation is asso-
ciated with bleeding from ulcer induced by this procedure. 
Treatment with proton pump inhibitors after variceal ligation 
significantly reduces the size of these ulcers and, ultimately, 
decreases the risk of bleeding [53].
The current standard treatment  
of portal hypertension in children
The most common causes of portal hypertension in 
children are biliary atresia and portal vein thrombosis. The 
data about prevalence of esophageal varices in children with 
portal hypertension are very limited and till now there have 
been no randomized controlled trials that would compare 
different methods of treatment for primary and secondary 
prevention [54].
About primary prevention, currently there are no clear 
treatment recommendations [55, 56]. Gathering of experts 
at the annual meeting of the American Association for Study 
of Liver Disease concluded that before getting the results of a 
randomized study in children, the pediatric research should 
focus on approach to the natural history and diagnosis of 
varices, the predictive factors of variceal bleeding, optimal 
therapy with β-blockers and endoscopic variceal ligation and 
alternative methods of treatment to assess therapeutic efficacy 
in children [57]. The management of acute variceal bleeding 
in children is based on the use of vasoactive agents, antibiotic 
prophylaxis and endoscopic variceal ligation. In children with 
portal vein thrombosis, the meso-rex by-pass seems to be the 
best option for secondary prophylaxis [55, 56, 58].
Conclusions
The elective treatment for the prevention of variceal 
hemorrhage is a combination of pharmacologic therapy 
(nonselective β-blockers ± isosorbide 5-mononitrate) and 
endoscopic variceal ligation. The assessment of bleeding 
risk is difficult, but the most important predictor of recur-
rent bleeding is evolutionary stage of cirrhosis Child-Pugh. 
The patients with Child-Pugh A class cirrhosis need to 
apply a single method of treatment, while patients with 
advanced liver disease require a combined therapy. Pati-
ents who have failed this therapy should be considered for 
TIPS placement, or surgical shunt. Patients with recurrent 
variceal bleeding are in a state of “continuous decompen-
sation” of liver cirrhosis and, as such, should be evaluated 
for liver transplantation.
In the last two decades significant advances in the mana-
gement of portal hypertension have improved the survival of 
patients with liver cirrhosis and portal hypertension. Were 
developed treatment strategies and well-established thera-
peutic options for each clinical stage and were identified 
different subpopulations of patients who require differentiated 
management.
 It is evident the necessity to perform new research directed 
towards identifying new pharmacological options that would 
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allow to get a positive hemodynamic response in most patients 
and thus would give up on the necessity to determine HVPG 
and may even give up on endoscopic therapy.
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